Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Marta, Dąbrowska" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR+DASABUVIR IN CHRONIC HEPATITIS C PATIENTS WITH HCV GENOTYPE 1 INFECTION
Autorzy:
Tatara, Tomasz
Dąbrowska-Bender, Marta
Staniszewska, Anna
Duda-Zalewska, Aneta
Powiązania:
https://bibliotekanauki.pl/articles/895553.pdf
Data publikacji:
2019-08-30
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
safety
hepatis C
ombitasvir/paritaprevir/ritonavir+dasabuvir
Opis:
Introduction The assessment of the safety profile of ombitasvir/paritaprevir/ritonavir+dasabuvir in adult chronic hepatitis C patients with confirmed HCV genotype 1 presence. Material and method Evaluation of clinical safety based on the results of primary studies found in the systematic review. The following literature databases were searched: Medline, Embase, Cochrane Library and others. Results Finally two clinical trial met the inclusion criteria. The study included untreated patients (SAPPHIRE I) or patients after unsuccessful therapy (SAPPHIRE II), with genotype 1 infection. In patients without prior treatment the prevalence of the reported adverse events was in general statistically significantly greater in the group on therapy 3D+RBV compared to the placebo group. No statistically significant differences were observed in relation to the risk of serious adverse events or therapy discontinuance due to adverse events. In patients after unsuccessful therapy the prevalence of the reported adverse events was statistically significantly greater in the group on therapy 3D+RBV compared to the placebo group. During the 3D+RBV itching was statistically significantly more frequently reported in the placebo group. Compared to the other adverse events, no statistically significant differences were observed. Conclusions Interferon-free therapies provide a safe therapeutic option in the population of adult patients with chronic genotype 1 hepatitis C, both those untreated and after unsuccessful two-drug PegIFNα-based therapy, patients with HIV co-infection and patients after liver transplantation.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 4; 613-620
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
COMPARISON OF PERSONALIZED AND STANDARD PROPHYLAXIS BASED ON OCTOCOG ALFA IN PEDIATRIC PATIENTS WITH HEMOPHILIA A
Autorzy:
Tatara, Tomasz
Dąbrowska-Bender, Marta
Duda-Zalewska, Aneta
Staniszewska, Anna
Kurek, Magdalena
Powiązania:
https://bibliotekanauki.pl/articles/895493.pdf
Data publikacji:
2020-04-29
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
Hemophilia A
octocog alfa
prophylaxis
Opis:
Comparison of personalized and standard prophylaxis prevention therapies based on octocog alfa in pediatric patients with hemophilia A. Studies on a general population (adults and children) demonstrate a statistically significant advantage of personalized prevention therapy over standard prophylaxis prevention therapy in terms of annual bleeding rate (ABR) and annual joint bleeding rate (AJBR) while studies on a pediatric population included insufficiently large populations, however, their results demonstrate a numerical advantage of personalized approach over standard prevention strategy prophylaxis regimen.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 2; 221-218
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies